All In MedTech

Device Trial Radar · NCT03701958

Initial Case Series With Exalt Single-Use Duodenoscope

Last checked: Nov 19, 2026Latest source record: Feb 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Apr 15, 2019

Primary completion

May 6, 2019

Study completion Jun 7, 2019

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Oct 10, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To confirm procedural performance of the Exalt single-use duodenoscope in Endoscopic Retrograde Cholangio-Pancreatography (ERCP) procedures.

Conditions

  • Endoscopic Retrograde Cholangiopancreatography

Interventions

  • Exalt Model D Single-Use DuodenoscopeDevice

    Subjects will have a clinically indicated per standard of care ERCP procedure performed with the Exalt single use duodenoscope study device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Successful ERCP procedureTime frame: Procedure success is assessed at the end of the procedure (within 24 hours on study day 1).

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Ronald Reagan University of California Los Angeles Medical Center

    Los Angeles, California

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.